©istock.com/Andrea Obzerova
Interdisciplinary CompetenceMolecular Diagnostics
Know how in the analysis of genetic material.
For the benefit of patients.

IllnessPituitary hormone deficiency, differential diagnosis

Summary

Short information

Comprehensive differential diagnostic panel for Pituitary hormone-deficiency, differential diagnosis, comprising 18 core-candodate genes and altogether 50 curated genes according to the clinical signs

ID
HP1250
Number of genes
40 Accredited laboratory test
Examined sequence length
23,3 kb (Core-/Core-canditate-Genes)
93,2 kb (Extended panel: incl. additional genes)
Analysis Duration
on request
Test material
  • EDTA-anticoagulated blood (3-5 ml)
Diagnostic indications

NGS +

[Sanger]

 

Gene panel

Selected genes

NameExon Length (bp)OMIM-GReferenz-Seq.Heredity
FGF8735NM_033163.5AD
FOXA21392NM_021784.5AD
GH1654NM_000515.5AD, AR
GHR1917NM_000163.5AR, AD
GHRHR1272NM_000823.4AR
GHSR1101NM_198407.2AD, AR
GLI24761NM_005270.5AD
GNRHR987NM_000406.3AR
HESX1558NM_003865.3AD, AR
LHX31209NM_014564.5AR
LHX41173NM_033343.4AD
OTX2870NM_172337.3AD
POU1F1876NM_000306.4AD, AR
PROP1681NM_006261.5AR
SHH1389NM_000193.4AD
SOX2954NM_003106.4AD
SOX31341NM_005634.3XLR
TBX191347NM_005149.3AR
ARNT22154NM_014862.4AR
BRAF2301NM_004333.6AD
BTK1980NM_000061.3XLR
CDON3795NM_016952.5AD
CHD78994NM_017780.4AD
FAT213050NM_001447.3AD
FGFR12469NM_023110.3AD
GLI34743NM_000168.6AD
IGSF14026NM_001170961.2XL
KCNQ12031NM_000218.3AD
NODAL1044NM_018055.5AD
PCSK12262NM_000439.5AR
PITX2816NM_153427.2AD
PNPLA63984NM_006702.5AR
PROKR21155NM_144773.4AD
PTCH14344NM_000264.5AD
RBM282280NM_018077.3AR
RET3345NM_020975.6AD
SIX3999NM_005413.4AD
TCF7L11767NM_031283.3AD
TGIF1819NM_173208.3AD
ZIC21599NM_007129.5AD

Informations about the disease

Clinical Comment

The anterior pituitary produces and secretes specific hormones such as growth hormone (GH), prolactin (PRL), thyroid-stimulating hormone (TSH), luteinizing hormone (LH), follicle-stimulating hormone (FSH) and adrenocorticotropic hormone (ACTH). Notably, early-acting factors that participate in pituitary organogenesis are not pituitary-specific but are also required for the development of other organs and structures. Lesions in these genes may also cause defects in the development of craniofacial, sensory or many other structures. Instead, factors acting later in the specification of pituitary cell lineages tend to be specific to each cell type, but are not necessarily restricted to the developing or mature pituitary. Impaired expression or function of these factors causes disorders in the pituitary gland and eventually leads to deficient secretion of pituitary hormones. Therefore, this panel includes many genes whose malfunction can lead to a very wide range of clinical symptoms. All monogenic and also multifactorial inheritance patterns are observed. Completely penetrant mutations in known genes are identified in 20-30% of familial cases. However, the overall DNA diagnostic yield is currently unknown, so a clinical diagnosis can by no means be ruled out by a negative molecular genetic result.

References: https://www.ncbi.nlm.nih.gov/books/NBK1347/

https://www.ncbi.nlm.nih.gov/books/NBK97965https://www.ncbi.nlm.nih.gov/books/NBK1334//

https://www.ncbi.nlm.nih.gov/books/NBK476671/

 

Synonyms
  • Allelic: Mitochondrial complex II deficiency, nuclear type 1 (SDHA)
  • Alias: Combined pituitary hormone deficiency, included
  • Alias: Congenital combined pituitary hormone deficiency, included
  • Alias: Congenital hypopituitarism, included
  • Alleic: Atrial fibrillation, familial, 3 (KCNQ1)
  • Alleic: Long QT syndrome 1 (KCNQ1)
  • Allelic. Cardiomyopathy, dilated, 1GG (SDHA)
  • Allelic. Mitochondrial complex II deficiency, nuclear type 4 (SDHB)
  • Allelic: Agammaglobulinemia, X-linked 1 (BTK)
  • Allelic: Anterior segment dysgenesis 4 (PITX2)
  • Allelic: Axenfeld-Rieger syndrome, type 1 (PITX2)
  • Allelic: Basal cell carcinoma, somatic (PTCH1)
  • Allelic: Basal cell nevus syndrome (PTCH1)
  • Allelic: Carcinoid tumor of lung (MEN1)
  • Allelic: Colorectal cancer, hereditary nonpolyposis, type 1 (MSH2)
  • Allelic: Colorectal cancer, hereditary nonpolyposis, type 2 (MLH1)
  • Allelic: Colorectal cancer, hereditary nonpolyposis, type 4 (PMS2)
  • Allelic: Colorectal cancer, hereditary nonpolyposis, type 5 (MSH6)
  • Allelic: Encephalocraniocutaneous lipomatosis, somatic mosaic (FGFR1)
  • Allelic: Endometrial cancer, familial (MSH6)
  • Allelic: Gastrointestinal stromal tumor (SDHB, SDHC)
  • Allelic: Greig cephalopolysyndactyly syndrome (GLI3)
  • Allelic: Hartsfield syndrome (FGFR1)
  • Allelic: Hirschsprung disease, protection against (RET)
  • Allelic: Hirschsprung disease, susceptibility to, 1 (RET)
  • Allelic: Holoprosencephaly 3 (SHH)
  • Allelic: Holoprosencephaly 9 (GLI2)
  • Allelic: Hypercholesterolemia, familial, modifier of (GHR)
  • Allelic: Increased responsiveness to growth hormone (GHR)
  • Allelic: Jackson-Weiss syndrome (FGFR1)
  • Allelic: Kowarski syndrome (GH1)
  • Allelic: Laron dwarfism (GHR)
  • Allelic: Long QT syndrome 1, acquired, susceptibility to (KCNQ1)
  • Allelic: Medullary thyroid carcinoma (RET)
  • Allelic: Mental retardation, XL, with isolated growth hormone deficiency (SOX3)
  • Allelic: Microphthalmia with coloboma 5 (SHH)
  • Allelic: Microphthalmia, syndromic 3 (SOX2)
  • Allelic: Microphthalmia, syndromic 5 (OTX2)
  • Allelic: Mitochondrial complex II deficiency, nuclear type 3 (SDHD)
  • Allelic: Muir-Torre syndrome (MLH1, MSH2)
  • Allelic: Myxoma, intracardiac (PRKAR1A)
  • Allelic: Neurodegeneration with ataxia + late-onset optic atrophy (SDHA)
  • Allelic: Optic nerve hypoplasia + abnormalities of the central nervous system (SOX2)
  • Allelic: Osteoglophonic dysplasia (FGFR1)
  • Allelic: PCWH syndrome (SOX10)
  • Allelic: Pfeiffer syndrome (FGFR1)
  • Allelic: Pleuropulmonary blastoma (DICER1)
  • Allelic: Polydactyly, postaxial, types A1 + B (GLI3)
  • Allelic: Polydactyly, preaxial, type IV (GLI3)
  • Allelic: Precocious puberty, central, 1 (KISS1R)
  • Allelic: Retinal dystrophy, early-onset, with/-out pituitary dysfunction (OTX2)
  • Allelic: Rhabdomyosarcoma, embryonal, 2 (DICER1)
  • Allelic: Ring dermoid of cornea (PITX2)
  • Allelic: Schizencephaly (SHH, SIX3)
  • Allelic: Septooptic dysplasia (HESX1)
  • Allelic: Short QT syndrome 2 (KCNQ1)
  • Allelic: Single median maxillary central incisor (SHH)
  • Allelic: Spastic paraplegia 39, AR (PNPLA6)
  • Allelic: Trigonocephaly (FGFR1)
  • Allelic: Waardenburg syndrome, type 4C (SOX10)
  • ACTH-independent macronodular adrenal hyperplasia (GNAS)
  • Acrodysostosis 1, with/-out hormone resistance (PRKAR1A)
  • Adrenocorticotropic hormone deficiency (TBX19)
  • Alopecia, neurologic defects + endocrinopathy syndrome (RBM28)
  • Boucher-Neuhauser syndrome (PNPLA6)
  • Brain, CNS + PNS cancer [panelapp] (MLH1, MSH2, MSH6)
  • CHARGE syndrome (CHD7)
  • CHARGE syndrome (SEMA3E)
  • Cardioacrofacial dysplasia 2 (PRKACB)
  • Carney complex, type 1 (PRKAR1A)
  • Charcot-Marie-Tooth disease, demyelinating, type 1I (POLR3B)
  • Congenital complex pituitary hormone deficiency (FOXA2)
  • Cornelia de Lange syndrome 2 (SMC1A)
  • Culler-Jones syndrome (GLI2)
  • Developmental + epileptic encephalopathy 85, with/-out midline brain defects (SMC1A)
  • Encephalocraniocutaneous lipomatosis, somatic mosaic (FGFR1)
  • Goiter, multinodular 1, with/-out Sertoli-Leydig cell tumors (DICER1)
  • Growth hormone deficiency with pituitary anomalies (HESX1)
  • Growth hormone deficiency, isolated partial (GHSR)
  • Growth hormone deficiency, isolated, type IA, IB, II (GH1)
  • Growth hormone deficiency, isolated, type IV (GHRHR)
  • Growth hormone insensitivity, partial (GHR)
  • Heterotaxy, visceral, 5 (NODAL)
  • Holoprosencephaly (DISP1)
  • Holoprosencephaly 11 (CDON)
  • Holoprosencephaly 13, XL (STAG2)
  • Holoprosencephaly 2 (SIX3)
  • Holoprosencephaly 3 (SHH)
  • Holoprosencephaly 4 (TGIF1)
  • Holoprosencephaly 5 (ZIC2)
  • Holoprosencephaly 7 (PTCH1)
  • Holoprosencephaly [A-/Lobar, Microform, Midline interhemispheric v., Semilobar, Septooptic] (FOXH1)
  • Holoprosencephaly [A-/Lobar, Microform, Midline interhemispheric var., Semilobar, Septooptic] (GAS1)
  • Hypogonadotropic hypogonadism 1 with/-out anosmia, Kallmann syndrome 1 (ANOS1)
  • Hypogonadotropic hypogonadism 10 with-out anosmia (TAC3)
  • Hypogonadotropic hypogonadism 11 with/-out anosmia (TACR3)
  • Hypogonadotropic hypogonadism 12 with/-out anosmia (GNRH1)
  • Hypogonadotropic hypogonadism 13 with/-out anosmia (KISS1)
  • Hypogonadotropic hypogonadism 14 with/-out anosmia (WDR11)
  • Hypogonadotropic hypogonadism 15 with/-out anosmia (HS6ST1)
  • Hypogonadotropic hypogonadism 16 with/-out anosmia (SEMA3A)
  • Hypogonadotropic hypogonadism 17 with/-out anosmia (SPRY4)
  • Hypogonadotropic hypogonadism 18 with/-out anosmia (IL17RD)
  • Hypogonadotropic hypogonadism 19 with/-out anosmia (DUSP6)
  • Hypogonadotropic hypogonadism 2 with/-out anosmia (FGFR1)
  • Hypogonadotropic hypogonadism 20 with/-out anosmia (FGF17)
  • Hypogonadotropic hypogonadism 21 with anosmia (FLRT3)
  • Hypogonadotropic hypogonadism 22, with/-out anosmia (FEZF1)
  • Hypogonadotropic hypogonadism 3 with/-out anosmia (PROKR2)
  • Hypogonadotropic hypogonadism 4 with/-out anosmia (PROK2)
  • Hypogonadotropic hypogonadism 5 with/-out anosmia (CHD7)
  • Hypogonadotropic hypogonadism 6 with/-out anosmia (FGF8)
  • Hypogonadotropic hypogonadism 7 without anosmia (GNRHR)
  • Hypogonadotropic hypogonadism 8 with/-out anosmia (KISS1R)
  • Hypogonadotropic hypogonadism 9 with/-out anosmia (NSMF)
  • Hypogonadotropic hypogonadism [Lit.] (AXL)
  • Hypogonadotropic hypogonadism [panelapp] (IGSF10)
  • Hypothyroidism, central + testicular enlargement (IGSF1)
  • Immunodeficiency, common variable, 10 (NFKB2)
  • Isolated GnRH hormone deficiency (CCDC14)
  • Isolated gonadotropin-releasing hormone deficiency [] genereview (SRA1)
  • Isolated growth hormone deficiency, type III, with agammaglobulinemia (BTK)
  • Jervell and Lange-Nielsen syndrome (KCNQ1)
  • Johanson-Blizzard syndrome (UBR1)
  • Laurence-Moon syndrome (PNPLA6)
  • Leukodystrophy, hypomyelinating, 8, with/-out oligodontia +/- hypogonadotropic hypogonadism (POLR3B)
  • McCune-Albright syndrome, somatic, mosaic (GNAS)
  • Mismatch repair cancer syndrome 1 (MLH1)
  • Mismatch repair cancer syndrome 2 (MSH2)
  • Mismatch repair cancer syndrome 3 (MSH6)
  • Mismatch repair cancer syndrome 4 (PMS2)
  • Mullegama-Klein-Martinez syndrome (STAG2)
  • Multiple endocrine neoplasia 1 (MEN1)
  • Multiple endocrine neoplasia 1 [panelapp] (CDKN1A)
  • Multiple endocrine neoplasia 1 [panelapp] (CDKN2B)
  • Multiple endocrine neoplasia 1 [panelapp] (CDKN2C)
  • Multiple endocrine neoplasia IIA + IIB (RET)
  • Neurodevelopmental disorder with nonspecific brain abnormalities, with/-out seizures (DLL1)
  • Oliver-McFarlane syndrome (PNPLA6)
  • Optic nerve hypoplasia and abnormalities of the CNS (SOX2)
  • Osseous heteroplasia, progressive (GNAS)
  • Pallister-Hall syndrome (GLI3)
  • Panhypopituitarism, XL (SOX3)
  • Paraganglioma + gastric stromal sarcoma (SDHB, SDHC, SDHD)
  • Paragangliomas 1, with/-out deafness (SDHD)
  • Paragangliomas 3 (SDHC)
  • Paragangliomas 4 (SDHB)
  • Paragangliomas 5 (SDHA)
  • Pheochromocytoma (RET, SDHB, SDHD)
  • Pheochromocytoma, susceptibility to (MAX)
  • Pigmented nodular adrenocortical disease, primary, 1 (PRKAR1A)
  • Pituitary adenoma 1, multiple types (AIP)
  • Pituitary adenoma 2, GH-secreting (GPR101)
  • Pituitary adenoma 3, multiple types, somatic (GNAS)
  • Pituitary adenoma 4, ACTH-secreting, somatic (USP8)
  • Pituitary adenoma predisposition (AIP)
  • Pituitary hormone deficiency (KCNQ1)
  • Pituitary hormone deficiency (TCF7L1)
  • Pituitary hormone deficiency, combined, 1 (POU1F1)
  • Pituitary hormone deficiency, combined, 2 (PROP1)
  • Pituitary hormone deficiency, combined, 3 (LHX3)
  • Pituitary hormone deficiency, combined, 4 (LHX4)
  • Pituitary hormone deficiency, combined, 5 (HESX1)
  • Pituitary hormone deficiency, combined, 6 (OTX2)
  • Pseudohypoparathyroidism Ia, Ib, Ic (GNAS)
  • Pseudopseudohypoparathyroidism (GNAS)
  • Retinal dystrophy, early-onset, with/-out pituitary dysfunction (OTX2)
  • Waardenburg syndrome, type 2E, with/-out neurologic involvement (SOX10)
  • Webb-Dattani syndrome (ARNT2)
Heredity, heredity patterns etc.
  • AD
  • AR
  • XL
  • XLR
OMIM-Ps
  • Multiple OMIM-Ps
ICD10 Code

Bioinformatics and clinical interpretation

Test-Stärken

  • DAkkS-akkreditiertes Labor
  • EU-Richtlinie für IVD in Umsetzung
  • Qualitäts-kontrolliert arbeitendes Personal
  • Leistungsstarke Sequenzierungstechnologien, fortschrittliche Target-Anreicherungsmethoden und Präzisions-Bioinformatik-Pipelines sorgen für überragende analytische Leistung
  • Sorgfältige Kuratierung klinisch relevanter und wissenschaftlich begründeter Gen-Panels
  • eine Vielzahl nicht Protein-kodierender Varianten, die in unseren klinischen NGS-Tests mit erfasst werden
  • unser strenges Variantenklassifizierungsschema nach ACMG-Kriterien
  • unser systematischer klinischer Interpretations-Workflow mit proprietärer Software ermöglicht die genaue und nachvollziehbare Verarbeitung von NGS-Daten
  • unsere umfassenden klinischen Aussagen

Testeinschränkungen

  • Gene mit eingeschränkter Abdeckung werden gekennzeichnet
  • Gene mit kompletten oder partiellen Duplikationen werden gekennzeichnet
  • es wird angenommen, dass ein Gen suboptimal abgedeckt ist, wenn >90% der Nukleotide des Gens bei einem Mapping-Qualitätsfaktor von >20 (MQ>20) nicht abgedeckt sind
  • die Sensitivität der Diagnostik zur Erkennung von Varianten mit genannten Testeinschränkungen ist möglicherweise begrenzt bei:
  • Gen-Konversionen
  • komplexe Inversionen
  • Balancierte Translokationen
  • Mitochondriale Varianten
  • Repeat-Expansionen, sofern nicht anders dokumentiert
  • nicht kodierende Varianten, die Krankheiten verursachen, die von diesem Panel nicht mit abgedeckt werden
  • niedriger Mosaik-Status
  • Repeat-Blöcke von Mononukleotiden
  • Indels >50bp (Insertionen-Deletionen)
  • Deletionen oder Duplikationen einzelner Exons
  • Varianten innerhalb von Pseudogenen
  • die analytische Sensitivität kann geringer ausfallen werden, wenn die DNA nicht von amedes genetics extrahiert wurde

Laboratory requirement

  • Die in grün gezeigten Gene sind kuratiert und werden als Gen-Panel untersucht. Eine Erweiterung des Panels (blau gezeigte Gene, jeweils ebenfalls kuratiert) kann auf Anfrage erfolgen. Sofern unter "Erweitertes Panel" ein Minuszeichen angezeigt wird, sind nur Core-/Basis-Gene verfügbar.

  • Für die Anforderung einer genetischen Untersuchung senden Sie uns bitte die Krankheits-ID auf einem Überweisungsschein. Bitte die Material-Angabe beachten.

  • Für privat versicherte Patienten empfehlen wir einen Antrag auf Kostenübernahme bei der Krankenversicherung.

  • Die Untersuchung wird auch für Selbstzahler angeboten.